FDA and FTC warn About Mineral that its Puriton skin products are unapproved drugs with misleading COVID-19 claims.
What happened
FDA reviewed https://aboutmineral.com on March 25, 2021, and FTC reviewed it on March 30, 2021; both also cited linked social media pages. FDA found Puriton topical skin products offered for sale with claims that they mitigate, prevent, treat, diagnose, or cure COVID-19, including a claim that Puriton reduced SARS-CoV-2 by more than 99.8% in a lab test. FDA said these are unapproved new drugs and misbranded drugs—sold without FDA approval and with labeling that violates the law.
What FDA found
FDA says the products are unapproved new drugs because they are sold with COVID-19 claims without FDA approval.
FD&C Act section 505(a), 21 U.S.C. § 355(a)FDA says the products are misbranded, a labeling violation, because they make COVID-19 claims for an unapproved use.
FD&C Act section 502, 21 U.S.C. § 352FDA says introducing these products into interstate commerce is prohibited.
FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)FTC says the company advertised that Puriton can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence, including well-controlled human studies.
FTC Act, 15 U.S.C. 41 et seq.FTC notes that deceptive COVID-19 treatment, cure, prevention, or mitigation claims can carry civil penalties.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA asks the company to take immediate action to stop selling unapproved and unauthorized COVID-19 products and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the specific steps taken, steps to prevent recurrence, and related documentation. FTC also asks for an email to Richard Cleland at rcleland@ftc.gov within 48 hours describing actions to address its concerns.
Who should pay attention
- online sellers making COVID-19 health claims
- brands using social media to promote topical or spray products
- marketplaces and retailers listing unapproved COVID-19 products
This is a summary. Read the original letter on fda.gov.